Drug-labels.com

Diosporin Ointment Product Monograph

The product monograph is written for health professionals. Plain-language information for patients is in the patient medication information: pregnancy and breastfeeding.

Status:
Prescription (Rx) Current status: Dormant Facts
Strength:
3.5 MG / 10000 UNIT / 400 UNIT
Active ingredients:
ATC code:
Similar drugs:

Source: Health Canada – Drug Product Database (DPD) and product monographs · About this document

Product Monograph - Diosporin Ointment

ADVERSE REACTIONS

Adverse Reactions: Adverse reactions have occurred with the anti-infective components of DIOSPORIN Ophthalmic Ointment. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including itching, swelling, and conjunctival erythema (see WARNINGS). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Local irritation on instillation has also been reported.

DOSAGE AND ADMINISTRATION

Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

AVAILABILITY

SUPPLIED Tube of 3.5 g with ophthalmic tip.

STORAGE

Store at 15° to 25°C. Keep tightly closed when not in use. Keep out of reach of children.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02023792

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Diosporin Ointment

Rx or OTC
Prescription (Rx)?
DIN 02023792
Schedule(s) PRESCRIPTION
Active ingredient(s) Neomycin (neomycin sulfate) 3.5 MG, Polymyxin b sulfate 10000 UNIT, Bacitracin zinc 400 UNIT
Dosage form(s) Ointment
Route(s) of administration Ophthalmic, Topical
Drug class (WHO ATC)
  1. S Sensory organ drugs
    1. S01 Ophthalmologicals
      1. S01A Antiinfective ophthalmologics
        1. S01AA Antibiotics, ophthalmologic
          1. S01AA30 Combinations of different antibiotics
Company STERI-MED PHARMA INC.
Current status Dormant
Current status date November 8, 2023

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.